. Characterization of the portal signal in a nonsteady hyperglycemic state in conscious dogs. Am J Physiol Endocrinol Metab 284: E148-E155, 2003. First published September 11, 2002 10.1152/ajpendo.00079.2002To characterize the "portal signal" in a nonsteady hyperglycemic state, the kinetic relationship between net hepatic glucose balance (NHGB) and either hepatic glucose load (HGL) or plasma insulin level was determined during glucose infusion using a catheter technique in 36 conscious dogs. Glucose was infused intraportally (Po group) and peripherally (Pe group) at 39, 56, and 83 mol ⅐ kg Ϫ1 ⅐ min Ϫ1 over 2 h. There was a linear relationship between mean NHGB and either mean HGL or plasma insulin levels at each rate in either delivery (HGL: Po r ϭ 0.99, Pe r ϭ 0.95; insulin: Po r ϭ 99, Pe r ϭ 0.79). The threshold levels for net hepatic glucose uptake were 3.8 and 11.7 mmol/l for plasma glucose and 65 and 392 pmol/l for plasma insulin, respectively. The slope of the regression line against the abscissa was four times larger in portal than in peripheral delivery (HGL: Po 0.20 vs. Pe 0.05, P Ͻ 0.05; insulin: Po 0.19 vs. Pe 0.04, P Ͻ 0.05). These results suggest that the portal signal overrules the threshold of glucose for hepatic uptake by increasing hepatic extraction rate in a nonsteady hyperglycemic state.
NUMEROUS STUDIES HAVE DOCUMENTED that hepatic glucose uptake is dependent on hepatic glucose load (HGL), plasma insulin level, and route of glucose delivery. However, in most studies, either hyperinsulinemic or hyperglycemic clamps were used in the presence of constant glucose, insulin, glucagon, and/or somatostatin concentrations (1, 2, 6, (14) (15) (16) . It has not been demonstrated yet whether the portal signal functions similarly in a nonsteady hyperglycemic state as in the case during a clamp state. Moore et al. (13) infused glucose at a gradually increasing rate via the portal and peripheral delivery routes in dogs, with insulin and glucagon being free to change. However, arterial and portal plasma glucose profiles were largely not different with time in either delivery. In many clamp studies, peripheral delivery was combined with portal delivery to keep hepatic load constant. However, the portal signal appears not to be associated with the magnitude of arterial-portal glucose gradients at high glucose load (16) . Recently, it has been reported that somatostatin blocks activation of the glucose sensor (5) . Furthermore, several studies have demonstrated that pulsatile insulin concentrations have greater effects on glucose uptake than a constant concentration (3, 7, 11, 17) , and the initial acute rise in plasma insulin provokes a decrease in postprandial hyperglycemia (4, 10) . Against this background, the present studies were undertaken to characterize the portal signal in a nonsteady hyperglycemic state. To this end, we determined the kinetic relationship between hepatic glucose disposal and HGL, plasma insulin levels, arterial-portal glucose gradients, or nonhepatic glucose uptake during intraportal and peripheral glucose infusion at the same rates.
MATERIALS AND METHODS
Animals. Experiments were carried out in 36 nondiabetic conscious beagles (7ϳ12 kg) of either sex fed daily a commercial pellet of meat and chow (Labo D standard meat, Nosan Tokyo; 24% protein, 66.5% carbohydrate, 8.4% fat, and 1.1% fiber based on dry weight). The protocols were approved by the Institute's Animal Care Committee.
Surgical procedures. Two weeks before the experiment, a laparotomy was performed in beagles under general anesthesia (35 mg/kg pentobarbital sodium), and polyethylene catheters (Nipro; Heparin Infusion Line, Osaka, Japan) were inserted into a mesenteric vein, the portal vein, the left common hepatic vein, and a femoral artery. The mesenteric catheter used for blood sampling was inserted via the superior mesenteric vein, and the tip was placed at the point where the vessel enters the liver. The tip of the other mesenteric catheter, used for glucose infusion into the portal vein, was placed ϳ4 cm downstream from the root of the superior mesenteric vein. The tip of the hepatic vein catheter used for blood sampling was placed 1 cm inside the left common hepatic vein. The femoral catheter used for blood sampling was inserted through an incision made in the left inguinal region. After the procedures, the catheters were filled with saline containing heparin (50 U/ml; Novo Nordisk Pharma, Copenhagen, Denmark). Probes of an ultrasonic range-gated, pulsed Doppler flowmeter (Instrumentation Development Laboratories, Bayler College of Medicine, Houston, TX) were placed around the portal vein and the hepatic artery. The gastroduodenal branches of the hepatic artery were ligated to prevent outflow from bypassing the liver. The free ends of the catheters and wires of the Doppler flow probes were exteriorized below the base of the skull. Only dogs with good appetite and normal blood count and serum enzymes were studied. On the day of experiment, 2 wk after surgery, the catheter contents were aspirated, the catheters were flushed with saline, and a catheter was inserted percutaneously into the left cephalic vein for the peripheral infusion of glucose. Each dog rested quietly in a Pavlov harness for the duration of the study.
Experimental design. Before the experiments, animals were fasted for 18 h but had access to water. Each experiment consisted of a 60-min basal period followed by a 120-min glucose infusion period. The nondiabetic animals were randomly assigned to either protocol 1 Calculations. Net hepatic glucose balance (NHGB) is defined as the difference between the load of glucose leaving the liver (LOADOUT) and that entering it (LOADIN). LOADOUT was calculated using the equation 
To assure the glucose mixing in the portal vein, we calculated NHGU with formulas 1 and 2. The difference in NHGU between the two formulas was Յ11% (Table 1). Timed net hepatic fractional extraction of glucose (NHFEG) was calculated by NHGU divided by HGL (%) at each time point during glucose infusion. Overall NHFEG was determined by cumulative areas under the curves (AUCs) of NHGU divided by cumulative AUCs of HGL (%). Net nonhepatic glucose uptake was calculated as glucose infusion rate minus mean AUCs of NHGU. The trapezoidal rule was used to determine the AUC.
Because canine red blood cells can act as glucose carriers, the most accurate assessment of gut glucose balance is obtained using blood glucose values. Plasma glucose values were used to determine the arterial-venous difference accurately, and then they were corrected to whole blood glucose by use of a blood glucose-to-plasma glucose ratio, Statistical analysis. Data are given as means Ϯ SE. Analysis of variance (ANOVA) with a repeated-measures design was utilized to evaluate changes over time within the groups at the respective infusion rate. Unpaired t-tests were used for comparison of the data at the particular rates between the two delivery routes. Paired t-tests were used for the comparison in NHGU between the direct and indirect measurements and between net NHGU and nonhepatic glucose uptake. The time course data were plotted at 13 time points during glucose infusion with each delivery rate. The mean data over 120 min during glucose infusion with the respective infusion rates were expressed as cumulative AUCs up to the arbiter time point divided by the minute number. The method of least squares was used to obtain a linear regression equation. A P value Ͻ 0.05 was accepted as significant. Figure 1 shows changes in plasma glucose, insulin, and glucagon levels in a femoral artery when groups of six dogs were infused with glucose intraportally (left) or peripherally (right) over 120 min at the rate of 39, 56, or 83 mol ⅐ kg Ϫ1 ⅐ min
RESULTS

Blood glucose levels during intraportal or peripheral glucose infusion.
Ϫ1
. As shown in Fig. 1 , top left, during intraportal infusion, plasma glucose increased gradually to a maximum at 60 min of 1.7, 1.9, and 2.5 times basal level at increasing doses and declined thereafter. Mean plasma glucose levels over 120 min increased dose dependently (P Ͻ 0.05) ( Table 2 ). Similar plasma glucose excursions were observed in the portal vein and the hepatic vein (data not shown).
As shown in Fig. 1 , top right, when glucose was infused into a cephalic vein, plasma glucose rose dose dependently to a maximum by 60 min of 1.5, 2.1, and Values are means Ϯ SE; n ϭ 6. NHGU, net hepatic glucose uptake. There are no significant differences between direct and indirect calculations (paired t-test). * Significant differences within rates (P Ͻ 0.05, ANOVA). 3.1 times basal level and leveled off thereafter. Mean plasma glucose levels increased with increasing infusion rates (P Ͻ 0.05) and tended to be greater in peripheral than in portal delivery, but the difference did not reach significance (Table 2) . Changes in portal and hepatic venous levels were similar to those in arterial levels (data not shown), but the mean portal plasma glucose level was two times higher in portal than peripheral delivery.
Plasma insulin levels. Figure 1 , middle, depicts the plasma insulin profiles during either glucose infusion. Basal plasma insulin levels were not different ( Table  2) . Plasma insulin increased gradually to a peak at 120 min of 3.4, 7.7, and 10.2 times basal level during intraportal delivery and 4.9, 8.9, and 7.9 times basal level at 45-105 min during peripheral delivery. Mean plasma insulin levels increased with increasing rates (P Ͻ 0.05) without any difference between the delivery routes ( Table 2 ). Portal and hepatic venous insulin excursions changed similarly throughout the experimental period, but mean plasma insulin levels in the portal vein were about twice as high as those in the artery.
Plasma glucagon levels. Plasma glucagon declined dose dependently to a nadir at 30-60 min via either route (Fig. 1, bottom) . Mean plasma glucagon levels were suppressed by 32, 23, and 32% during portal delivery and by 28, 45, and 51% during peripheral delivery; these differences were not significant within doses and between delivery routes except for the mid- dle rate (Table 1) . Basal glucagon levels were slightly lower in the order of portal vein, hepatic vein, and artery, and portal and hepatic venous glucagon decreased from basal levels to the same extent during glucose infusion in either delivery (data not shown).
Hepatic blood flow. As shown in Table 3 , blood flows were higher during portal than during peripheral delivery. Portal vein blood flow tended to decrease, whereas hepatic arterial blood flow did not change in either delivery route. Neither blood flow increased with increasing glucose delivery rates in either route. Portal vein blood flow was 3.4-4.6 times higher than hepatic arterial blood flow during portal delivery and 3.0-3.2 times higher during peripheral delivery.
HGL. Figure 2 , top, shows changes in HGL during basal and glucose infusion periods. Basal HGL was not significantly different at any rate or route except for the middle rate ( Table 4) . As shown in Fig. 2 , top left, during intraportal glucose infusion, HGL increased dose dependently to a maximum at 45-60 min of 2.0, 2.1, and 2.9 times basal load. The maximal values and mean AUCs of HGL increased with increasing rates (P Ͻ 0.05; Table 4 ). Portal glucose infusion rates corresponded to 21, 22, and 24% of mean HGL, respectively. There was a moderate correlation between HGL and plasma insulin level (r ϭ 0.41, P Ͻ 0.005).
As depicted in Fig. 2 , top right, during peripheral glucose infusion, HGL rose to a peak at 20-60 min of 1.4, 2.0, and 2.5 times basal. The maximal values and mean HGL were raised with increasing rates (P Ͻ 0.05; Table 4 ). Peripheral glucose infusion rates corresponded to 33, 42, and 35% of mean HGL, respectively. Mean HGL was 1.6, 1.9, and 1.4 times greater during intraportal than peripheral delivery at the respective rate (P Ͻ 0.05). There was an approximately linear relationship between HGL and portal insulin levels in either delivery (Po r ϭ 0.92; Pe r ϭ 0.91).
NHGB. As illustrated in Fig. 2 , bottom, there was a great difference in NHGB, net release, or net uptake, according to the delivery routes. As shown on the left, as soon as glucose was delivered into the portal vein, the liver switched from net glucose release to net consumption of glucose. NHGU attained the earlier and higher maximum with increasing doses [20.6 Ϯ 8.3 (t max ϭ 2 min); Ϫ39.4 Ϯ 3.3 (2 min); and Ϫ70.0 Ϯ 7.8 mol ⅐ kg Ϫ1 ⅐ min
(20 min), respectively]. Mean NHGU increased with increasing rates (P Ͻ 0.05). The latter corresponded to 46, 53, and 59% of the intrapor- Values are means Ϯ SE; n ϭ 6. AUC, area under the curve. † Mean values were expressed as cumulative AUCs up to the arbiter time point divided by the time. ‡ Significant difference between intraportal and peripheral glucose infusion (P Ͻ 0.05, nonpaired t-test). * Significant difference among the infusion rates (P Ͻ 0.05, ANOVA). There are no significant differences of basal level within groups. * * * * * * * * Values are means Ϯ SE; n ϭ 6. There was no difference in blood flow between basal and mean AUCs at any infusion rates. † Mean values were expressed as cumulative AUCs up to the arbiter time point divided by the minute number. ‡ Significant difference between intraportal and peripheral glucose infusion (P Ͻ 0.05 nonpaired t-test).
tally infused glucose (Table 5 ). In contrast, as shown in Fig. 2 , bottom right, when glucose was given peripherally, the liver ceased gradually to release glucose by 30 min and removed only negligible amounts of glucose thereafter, if at all.
Relationship between NHGB and HGL. Figure 3 depicts a linear relationship between mean AUCs of NHGU and HGL over 120 min during glucose delivery at the respective rates in either delivery route (Po r ϭ Ϫ0.99, P Ͻ 0.01; and Pe r ϭ Ϫ0.95, P Ͻ 0.01). When the line relating them was extrapolated to the HGL axis, it intersected at 103 and 228 mmol ⅐ kg Ϫ1 ⅐ min Ϫ1 in portal and peripheral delivery, respectively. These HGL values corresponded to 3.8 and 11.7 mmol/l for plasma glucose levels. The slope of the regression line was three times larger in portal than in peripheral delivery (0.21 vs. 0.07, P Ͻ 0.05). NHFEG, the ratio of NHGU to HGL, immediately reached maximum and sustained Values are means Ϯ SE; n ϭ 6. * Significant difference among the infusion rates (P Ͻ 0.05, ANOVA). † Mean values were expressed as cumulative AUCs up to the arbitary time point divided by the minute number. ‡ Significant difference between intraportal and peripheral glucose infusion (P Ͻ 0.05, nonpaired t-test) .
the level thereafter during intraportal glucose infusion. Mean AUCs of NHFEG were 11.5 Ϯ 0.4, 11.0 Ϯ 1.1, and 15.6 Ϯ 1.5% at the corresponding rates.
Relationship between NHGB and plasma insulin level. As illustrated in Fig. 4 , an approximately linear relationship was also achieved between mean NHGB and plasma insulin levels over 120 min during portal and peripheral delivery at the respective rates (Pe r ϭ 0.76, P Ͻ 0.05; Po r ϭ 0.99, P Ͻ 0.01). The intercepts of the regression line on the insulin axis were 392 and 65 pmol/l during portal and peripheral delivery, respectively. Thus the threshold insulin value for hepatic glucose uptake in portal delivery was one-sixth that in peripheral delivery. The slope of the regression line of NHGB against insulin axis was about four times larger in portal than in peripheral delivery (Po 0.19 vs. Pe 0.044). A similar linear relationship was also observed between NHGB and portal insulin levels in either delivery (Po r ϭ 0.99; Pe r ϭ 0.98).
Relationship between NHGB and arterial-portal glucose gradient. As shown in Fig. 5 , a linear relationship was observed between mean NHGU and negative arterial-portal glucose gradients over 120 min during glucose delivery at each rate in either delivery route (Po r ϭ 0.98, Pe r ϭ 0.99). NHGU was negligible at Statistics were not carried out because nonhepatic glucose uptake could not be estimated precisely, and plasma glucose levels did not decline to the baseline levels during glucose delivery. positive arterial-portal glucose gradients during peripheral glucose load.
Relationship between NHGU and nonhepatic glucose uptake. Table 5 shows the comparison of mean NHGU and nonhepatic glucose uptake over 120 min during portal glucose delivery at each rate. Contrary to NHGU, nonhepatic glucose uptake decreased dose dependently. As a consequence, nonhepatic glucose uptake was smaller than NHGU except for the low dose.
DISCUSSION
In this study, we show approximately linear relationships between mean NHGB and HGL over 120 min during glucose delivery at the respective rates via either route (Fig. 3) . The regression line indicates that the threshold of plasma glucose for hepatic glucose uptake was largely at basal level for portal delivery, whereas it was over twice the basal level for peripheral delivery, and the slope of the regression line was about four times larger in portal than in peripheral delivery. Thus the portal signal appears to open the slope and overrule the glucose threshold for hepatic glucose uptake. In other words, the liver removes glucose newly entering the portal vein by raising the rate of glucose extraction by the portal signal. The correlation coefficient appeared to be similar in either route to those reported in the clamp study by Myers et al. (14) . During peripheral infusion, the threshold and the slope were comparable in both studies. This means that the low slope may be a proper nature of peripheral delivery and is not limited to hepatic glucose output. During portal delivery, the threshold of plasma glucose was at nearly basal level in both studies, but the slope was four times larger in our study. With these results taken together, we believe that the portal signal is operative more sensitively in a nonsteady hyperglycemic state than in a hyperglycemic hyperinsulinemic clamp state if the portal signal was represented as the degree of the angle. In general, NHFEG (NHGU/HGL) is used as a measure of hepatic glucose extraction. The observed mean NHFEG values (11.0-15.6%) were comparable to those reported by Galassetti et al. (8) , Horikawa et al. (9) , and Moore et al. (12) . However, our study indicates that NHGU can be expressed as such a linear equation of HGL with an intercept that NHFEG is inappropriate to evaluate hepatic extraction rate.
Mean NHGU over a 120-min glucose delivery was linearly related to mean plasma insulin level during glucose delivery at the respective rate in either delivery route (r ϭ 0.99; Fig. 4 ). However, there was a great difference in the intercepts and the slopes: the threshold insulin level for NHGU in portal delivery was one-sixth that of peripheral delivery, whereas the slope against the insulin axis was four times that of peripheral delivery. Thus no hepatic glucose uptake was promoted at mean arterial insulin levels of 380 pmol/l during peripheral glucose delivery. This result suggests that plasma insulin plays a minor role in hepatic glucose uptake relative to HGL. However tightly associated arterial-portal glucose gradients are with the increases in HGL and plasma insulin level, from the result described above it was difficult to dissociate effects of one from the other in our preparation.
It remains uncertain whether negative arterial-portal glucose gradients are a cause or a consequence of the portal signal. In this study, an approximately linear relationship was observed between mean NHGU and negative arterial-portal glucose gradients at the particular rates (Fig. 5) . This result partly argues against the study of Pagliassotti et al. (16) . Those authors showed that NHGU was raised with increasing arterial-portal glucose gradient but was saturated when the gradient was Ͼ0.8 mmol/l in the presence of fixed hepatic glucose and insulin load. Therefore, combined peripheral glucose administration with portal delivery is likely to affect the linear relationship between NHGU and arterial-portal glucose gradient.
Plasma glucose concentrations plateaued during peripheral delivery, whereas they declined during portal glucose delivery at the high dose, although plasma insulin continued to increase similarly in either delivery (Fig. 1) . The plasma glucose profile may be the consequence of changes in HGL, NHGB, and/or nonhepatic glucose uptake. NHGU was negligible, and nonhepatic glucose uptake was equated with glucose delivery rates during peripheral delivery ( Table 5) . As a result, plasma glucose levels would have been equilibrated. On the other hand, plasma glucose level and HGL began to decrease 60 min after the commencement of portal glucose delivery ( Figs. 1 and 2 ). Mean NHGU occupied ϳ60% of the glucose infusion rate during portal glucose infusion and overestimated nonhepatic glucose uptake was as low as ϳ40% of peripheral glucose infusion (Table 5) . Together, the increase in hepatic glucose uptake and hepatic glycogen synthesis may have resulted in the decline in plasma glucose level with increasing plasma insulin level during portal delivery. However, it remains unclear why the plasma insulin level tends to rise despite the decline in plasma glucose.
We conclude that the portal signal operates more sensitively in a nonsteady hyperglycemic state than in a hyperglycemic hyperinsulinemic state, because it obliterates the glucose threshold for NHGU by increasing the rate of hepatic glucose extraction.
